Neuropathix (NPTX) 10-Q 13 May 21 2021 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2021	May 11, 2021
Document And Entity Information
Entity Registrant Name	NEUROPATHIX, INC.
Entity Central Index Key	0001615999
Document Type	10-Q
Document Period End Date	Mar. 31, 2021
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity's Reporting Status Current	Yes
Is Entity Emerging Growth?	true
Is Entity Small Business?	true
Entity Extended Transition Period?	false
Entity Shell Company	false
Entity Filer Category	Non-accelerated Filer
Entity Incorporation, State or Country Code	DE
Entity File Number	000-55657
Entity Interactive Data Current	Yes
Entity Common Stock, Shares Outstanding		87,978,445
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2021

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($)	Mar. 31, 2021	Dec. 31, 2020
CURRENT ASSETS:
Cash and cash equivalents	$ 323,190	$ 21,874
Prepaid expenses	38,000	161,000
Other receivables	56,838	400
Total Current Assets	418,028	183,274
NON-CURRENT ASSETS:
Property and equipment, net	79,458	59,266
Security deposits	17,121	17,121
Total Non-Current Assets	96,579	76,387
TOTAL ASSETS	514,607	259,661
CURRENT LIABILITIES:
Accounts payable and accrued expenses	550,275	721,308
Payroll and related liabilities	363,989	379,241
Loan payable	950,000	950,000
Loan payable - related party	42,092	42,092
Convertible notes payable, net of $146,371 debt discount	194,821	198,127
Convertible notes payable, net of $61,507 debt discount - related party	88,493	0
Capital lease obligations	12,860	8,471
Patent purchase liability	53,135	53,135
Due to related party, net	28,415	55,258
Derivative liabilities	157,184	138,046
Total Current Liabilities	2,441,264	2,545,678
LONG TERM LIABILITIES:
Convertible notes payable - long term	314,866	376,373
Convertible notes payable - long term - related party	0	70,000
Capital lease obligation - long term portion	29,416	19,293
Patent purchase liability - long term	204,826	264,826
Derivative liabilities - long term	201,149	178,143
Total Long Term Liabilities	811,764	908,635
TOTAL LIABILITIES	3,253,028	3,454,313
STOCKHOLDERS' DEFICIT:
Common stock, $0.0001 par value, 200,000,000 authorized, 87,978,445 and 77,670,908 issued and outstanding, respectively	8,797	7,767
Additional paid-in capital	11,614,719	9,830,944
Accumulated deficit	(14,361,937)	(13,033,363)
TOTAL STOCKHOLDERS' DEFICIT	(2,738,421)	(3,194,652)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	514,607	259,661
Series A Preferred Stock [Member]
STOCKHOLDERS' DEFICIT:
Preferred stock, $0.0001 par value, 5,000,000 shares authorized	0	0
Series B Preferred Stock [Member]
STOCKHOLDERS' DEFICIT:
Preferred stock, $0.0001 par value, 5,000,000 shares authorized	$ 0	$ 0

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - USD ($)	Mar. 31, 2021	Dec. 31, 2020
Debt discount current	$ 146,371
Debt discount related party	$ 61,507
Preferred Stock, Par or Stated Value Per Share	$ 0.0001	$ 0.0001
Preferred Stock, Shares Authorized	5,000,000	5,000,000
Common Stock, Par or Stated Value Per Share	$ 0.0001
Common Stock, Shares Authorized	200,000,000
Common Stock, Shares, Issued	87,978,445	77,670,908
Common Stock, Shares, Outstanding	87,978,445	77,670,908
Series A Preferred Stock [Member]
Preferred Stock, Shares Authorized	75	75
Preferred Stock, Shares Issued	75	75
Preferred Stock, Shares Outstanding	75	75
Liquidation preference	$ 75,000	$ 75,000
Series B Preferred Stock [Member]
Preferred Stock, Shares Authorized	75	75
Preferred Stock, Shares Issued	75	75
Preferred Stock, Shares Outstanding	75	75
Liquidation preference	$ 75,000	$ 75,000

Condensed Consolidated Statemen

Condensed Consolidated Statements Of Operations (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
NET REVENUES:
Grant revenue	$ 32,000	$ 0
TOTAL NET REVENUES	32,000	0
OPERATING EXPENSES:
Research and development	128,648	19,727
General and administrative	987,189	364,107
TOTAL OPERATING EXPENSES	1,115,837	383,834
LOSS FROM OPERATIONS	(1,083,837)	(383,834)
OTHER INCOME (EXPENSE)
Interest expense, net	(134,521)	(215,163)
Change in fair value of derivative liabilities	(110,216)	291,165
TOTAL OTHER INCOME (EXPENSE)	(244,737)	76,002
NET LOSS BEFORE INCOME TAX	(1,328,574)	(307,832)
Income tax expense	0	0
NET LOSS	$ (1,328,574)	$ (307,832)
Loss per common share - basic and diluted	$ (0.02)	$ 0
Weighted average common shares outstanding - basic and diluted	82,806,466	74,225,141

Condensed Consolidated Statem_2

Condensed Consolidated Statements Of Stockholders' Deficit (Unaudited) - USD ($)	Series A Preferred Stock	Series B Preferred Stock	Common Stock	Additional Paid-In Capital	Accumulated Deficit	Total
Beginning balance, Shares at Dec. 31, 2019	75	75	74,225,141
Beginning balance, Amount at Dec. 31, 2019			$ 7,422	$ 6,794,612	$ (8,496,088)	$ (1,694,054)
Net loss					(307,832)	(307,832)
Ending balance, Shares at Mar. 31, 2020	75	75	74,225,141
Ending balance, Amount at Mar. 31, 2020			$ 7,422	6,794,612	(8,803,920)	(2,001,886)
Beginning balance, Shares at Dec. 31, 2020	75	75	77,670,908
Beginning balance, Amount at Dec. 31, 2020			$ 7,767	9,830,944	(13,033,363)	(3,194,652)
Stock based compensation				453,950		453,950
Issuance of common stock for cash, Shares			7,268,188
Issuance of common stock for cash, Amount			$ 727	813,030		813,757
Issuance of common stock for conversion of notes payable and accrued interest, Shares			988,069
Issuance of common stock for conversion of notes payable and accrued interest, Amount			$ 99	89,632		89,731
Issuance of common stock for services, Shares			525,000
Issuance of common stock for services, Amount			$ 52	105,243		105,295
Issuance of common stock in lieu of deferred compensation, Shares			692,308
Issuance of common stock in lieu of deferred compensation, Amount			$ 69	89,931		90,000
Issuance of common stock due to settlement of accrued expenses, Shares			520,000
Issuance of common stock due to settlement of accrued expenses, Amount			$ 52	103,948		104,000
Issuance of common stock for payment of patent purchase liability, Shares			313,972
Issuance of common stock for payment of patent purchase liability, Amount			$ 31	59,969		60,000
Reduction of derivative liability				68,072		68,072
Net loss					(1,328,574)	(1,328,574)
Ending balance, Shares at Mar. 31, 2021	75	75	87,978,445
Ending balance, Amount at Mar. 31, 2021			$ 8,797	$ 11,614,719	$ (14,361,937)	$ (2,738,421)

Condensed Consolidated Statem_3

Condensed Consolidated Statements Of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (1,328,574)	$ (307,832)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	4,445	4,034
Amortization of debt discount	100,187	44,109
Stock based compensation	453,950	0
Issuance of common stock for services	157,294	0
Non-cash interest expense	0	149,604
Change in fair value of derivative liabilities	110,216	(291,165)
Changes in operating assets and liabilities:
Prepaid expenses	123,000	3,000
Accounts payable and accrued expenses	(114,302)	(5,036)
Payroll and related liabilities	74,748	30,302
Due to related party, net	(26,843)	23,912
NET CASH USED IN OPERATING ACTIVITIES	(445,879)	(349,072)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of equipment	(8,100)	0
NET CASH USED IN INVESTING ACTIVITIES	(8,100)	0
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock	757,320	0
Principal payments toward capital lease obligations	(2,025)	(1,801)
Proceeds from loan payable - related party	0	150,000
Proceeds from convertible notes payable, net of OID	0	194,000
NET CASH PROVIDED BY FINANCING ACTIVITIES	755,295	342,199
Net increase (decrease) in cash	301,316	(6,873)
Cash and cash equivalents, beginning of period	21,874	121,455
Cash and cash equivalents, end of period	323,190	114,582
SUPPLEMENTAL CASH FLOW INFORMATION:
Cash paid for interest	798	0
Cash paid for taxes	0	0
NON-CASH ACTIVITIES:
Issuance of common stock for conversion of notes payable and accrued interest	89,731	0
Issuance of common stock for payment of patent purchase liability	60,000	0
Issuance of common stock in lieu of deferred compensation	90,000	0
Receivable upon the issuance of common shares	56,438	0
Property and equipment financed through capital leases	16,537	0
Reduction of derivative liability	68,072
Settlement of accrued expenses through issuance of common stock	52,000	0
Debt discount upon the issuance of convertible note payable	0	194,000
Debt discount upon the issuance of convertible note payable - related party	$ 0	$ 150,000

Organization and Nature of Oper

Organization and Nature of Operations	3 Months Ended
	Mar. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Nature of Operations	Note 1 – Organization and Nature of Operations Neuropathix, Inc. (the “Company”) was incorporated under the laws of the state of Delaware on March 25, 2013 under the name TYG Solutions Corp. The Company consummated a share exchange transaction on July 25, 2018 with Kannalife Sciences, Inc. (“Kannalife”), a privately held Delaware corporation formed in 2010, the accounting acquirer. Upon completion of the share exchange transaction, Kannalife was treated as the surviving entity and accounting acquirer although the Company was the legal acquirer. Accordingly, the Company’s historical financial statements are those of Kannalife the surviving entity and accounting acquirer. All references that refer to (the “Company” or “we” or “us” or “our”) are Kannalife, unless otherwise differentiated. Kannalife is a phytomedical/pharmaceutical company that specializes in the research and development of synthetic molecules and therapeutic products derived from botanical sources, including the cannabis taxa. On November 9, 2018, the Company filed an amendment to its certificate of incorporation with the Delaware Secretary of State that changed its name to Kannalife, Inc. Name Change – Neuropathix, Inc. On November 4, 2020, the Company filed an amendment to its certificate of incorporation with the Delaware Secretary of State that changed its name to Neuropathix, Inc. The Company concurrently submitted a request to FINRA for approval of the name change as well as a ticker symbol change from “KLFE” to “NPTX.” The Company’s name change and ticker symbol change was reviewed and processed by FINRA and went effective November 6, 2020. Unaudited Interim Financial Information We have prepared the accompanying condensed consolidated financial statements pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”) for interim financial reporting. These condensed consolidated financial statements are unaudited and, in our opinion, include all adjustments, consisting of normal recurring adjustments and accruals necessary for a fair presentation of our balance sheets, operating results, and cash flows for the periods presented. Operating results for the periods presented are not necessarily indicative of the results that may be expected for 2021. Certain information and footnote disclosures normally included in consolidated financial statements prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) have been omitted in accordance with the rules and regulations of the SEC. These condensed consolidated financial statements should be read in conjunction with our audited financial statements and accompanying notes for the year ended December 31, 2020, included in the Company’s Annual Report on Form 10-K filed with the SEC on March 30, 2021.

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2021
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 2 - Summary of Significant Accounting Policies The significant accounting policies used in the preparation of the condensed consolidated financial statements are as follows: Basis of Presentation The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States, or GAAP. Significant Risks and Uncertainties The Company’s operations are subject to a number of factors that can affect its operating results and financial condition. Such factors include, but are not limited to: the results of clinical testing and trial activities of the Company’s products, the Company’s ability to obtain regulatory approval to market its products, competition from products manufactured and sold or being developed by other companies, the price of, and demand for, Company products, the Company’s ability to negotiate favorable licensing or other manufacturing and marketing agreements for its products, and the Company’s ability to raise capital. The Company currently has no commercially approved products and there can be no assurance that the Company’s research and development will be successfully commercialized. Developing and commercializing a product requires significant time and capital and is subject to regulatory review and approval as well as competition from other biotechnology and pharmaceutical companies. The Company operates in an environment of rapid change and is dependent upon the continued services of its employees and consultants and obtaining and protecting intellectual property. In December 2019, a novel strain of coronavirus, commonly known as COVID-19, surfaced. The spread of COVID-19 around the world in 2020 has caused significant volatility in U.S. and international markets. There is significant uncertainty around the breadth and duration of business disruptions related to COVID-19, as well as its impact on the U.S. and international economies and, as such, the Company is unable to determine if it will have a material impact to its operations. The Company’s operations as of March 31, 2021 have not been significantly affected, but may be affected in the future, by the ongoing outbreak of COVID-19 which was declared a pandemic by the World Health Organization. The ultimate disruption which may be caused by the outbreak is uncertain; however, it may result in a material adverse impact on the Company’s financial position, operations and cash flows. Possible areas that may be affected include, but are not limited to, disruption to the Company’s labor workforce, unavailability of products and supplies used in operations, and the decline in value of assets held by the Company. Use of Estimates The preparation of consolidated financial statements and accompanying notes in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the dates of the consolidated financial statements, and the reported amounts of revenues and expenses during the periods. Actual results could differ from those estimates. Significant matters requiring the use of estimates and assumptions include, but are not necessarily limited to, establishing the fair value of marketable securities and periodically evaluating marketable securities for potential impairment, fair value of the Company’s stock, stock-based compensation, valuation of derivative liabilities and valuation allowance relating to the Company’s deferred tax assets. Management believes that its estimates and assumptions are reasonable, based on information that is available at the time they are made. Net Loss per Share Basic net loss per share is calculated by dividing the net loss for the period by the weighted-average number of common shares outstanding during the period. Diluted net income per share is calculated by dividing income for the period by the weighted-average number of common shares outstanding during the period, increased by potentially dilutive common shares ("dilutive securities") that were outstanding during the period. Dilutive securities include stock options and warrants granted, convertible debt, and convertible preferred stock. The weighted average number of common stock equivalents not included in diluted income per share, because the effects are anti-dilutive, was 29,446,224 and 4,898,092 for the three months ended March 31, 2021 and 2020, respectively. Research and Development In accordance with FASB ASC 730, Research and Development Stock Based Compensation The Company accounts for share-based compensation in accordance with the fair value recognition provision of FASB ASC 718, Compensation – Stock Compensation (“ASC 718”), prescribes accounting and reporting standards for all share-based payment transactions in which employee services are acquired. Transactions include incurring liabilities, or issuing or offering to issue shares, options, and other equity instruments such as employee stock ownership plans and stock appreciation rights. Share-based payments to employees, including grants of employee stock options, are recognized as compensation expense, which is included in the general and administrative expense in the consolidated financial statements based on the estimated grant date fair values. That expense is recognized over the period during which an employee is required to provide services in exchange for the award, known as the requisite service period (usually the vesting period). Recently Issued Authoritative Guidance In June 2016, the FASB issued ASU 2016-13, “Financial Instruments – Credit Losses” to improve information on credit losses for financial assets and net investment in leases that are not accounted for at fair value through net income. ASU 2016-13 replaces the current incurred loss impairment methodology with a methodology that reflects expected credit losses. In April 2019 and May 2019, the FASB issued ASU No. 2019-04, “Codification Improvements to Topic 326, Financial Instruments-Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments” and ASU No. 2019-05, “Financial Instruments-Credit Losses (Topic 326): Targeted Transition Relief” which provided additional implementation guidance on the previously issued ASU. In November 2019, the FASB issued ASU 2019-10, “Financial Instruments - Credit Loss (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842),” which defers the effective date for public filers that are considered small reporting companies (“SRC”) as defined by the Securities and Exchange Commission to fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. Since the Company is an SRC, implementation is not needed until January 1, 2023. The Company will continue to evaluate the effect of adopting ASU 2016-13 will have on the Company’s consolidated financial statements.

Going Concern and Management's

Going Concern and Management's Liquidity Plans	3 Months Ended
	Mar. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Going Concern and Management's Liquidity Plans	Note 3 – Going Concern and Management’s Liquidity Plans The Company’s condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. As reflected in our accompanying condensed consolidated financial statements, the Company has had a net loss from operations of $1,083,837 and $383,834 for the three months ended March 31, 2021 and 2020, respectively. Additionally, the Company had an accumulated deficit of $14,361,937 at March 31, 2021 and has not yet established an adequate ongoing source of revenues sufficient to cover its operating costs and to allow it to continue as a going concern. These factors raise substantial doubt about its ability to continue as a going concern. In order to continue as a going concern, the Company will need, among other things, additional capital resources. Management plans to raise additional capital through the sale of convertible debt securities offering. However, there are no assurances that such additional funding will be achieved or that management’s plans will be successful. The accompanying condensed consolidated financial statements do not include any adjustments related to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

Fair Value Measurements

Fair Value Measurements	3 Months Ended
	Mar. 31, 2021
Fair Value Disclosures [Abstract]
Fair Value Measurements	Note 4 – Fair Value Measurements The Company follows FASB ASC 820, Fair Value Measurements and Disclosures Level 1 - Quoted market prices available in active markets for identical assets or liabilities as of the reporting date. Level 2 - Pricing inputs other than quoted prices in active markets included in Level 1, which are either directly or indirectly observable as of the reporting date. Level 3 - Pricing inputs that are generally unobservable inputs and not corroborated by market data. Financial assets are considered Level 3 when their fair values are determined using pricing models, discounted cash flow methodologies or similar techniques and at least one significant model assumption or input is unobservable. The fair value hierarchy gives the highest priority to quoted prices (unadjusted) in active markets for identical assets or liabilities and the lowest priority to unobservable inputs. If the inputs used to measure the financial assets and liabilities fall within more than one level described above, the categorization is based on the lowest level input that is significant to the fair value measurement of the instrument. The carrying amounts reported in the Company’s condensed consolidated financial statements for cash, accounts payable and accrued expenses approximate their fair value because of the immediate or short-term nature of these financial instruments. Transactions involving related parties cannot be presumed to be carried out on an arm's-length basis, as the requisite conditions of competitive, free-market dealings may not exist. Representations about transactions with related parties, if made, shall not imply that the related party transactions were consummated on terms equivalent to those that prevail in arm's-length transactions unless such representations can be substantiated. The following table presents liabilities that are measured and recognized at fair value as of March 31, 2021 and December 31, 2020, on a recurring basis: March 31, 2021 Level 1 Level 2 Level 3 Total Carrying Value Derivative liabilities — — 358,333 $ 358,333 December 31, 2020 Level 1 Level 2 Level 3 Total Carrying Value Derivative liabilities — — 316,189 $ 316,189

Accounts Payable and Accrued Ex

Accounts Payable and Accrued Expenses	3 Months Ended
	Mar. 31, 2021
Payables and Accruals [Abstract]
Accounts Payable and Accrued Expenses	NOTE 5 – ACCOUNTS PAYABLE AND ACCRUED EXPENSES Accounts payable and accrued expenses at March 31, 2021 and December 31, 2020 consisted of the following: March 31, 2021 December 31, 2020 Accounts payable and accrued expenses $ 339,961 $ 538,527 Accrued interest 210,314 182,781 Totals $ 550,275 $ 721,308

Payroll and Related Liabilities

Payroll and Related Liabilities	3 Months Ended
	Mar. 31, 2021
Payables and Accruals [Abstract]
Payroll and Related Liabilities	NOTE 6 – PAYROLL AND RELATED LIABILITIES Payroll and related liabilities at March 31, 2021 and December 31, 2020 consisted of the following: March 31, 2021 December 31, 2020 Payroll $ 120,234 $ 149,704 Payroll taxes 243,755 229,537 Totals $ 363,989 $ 379,241 As of March 31, 2021 and December 31, 2020, the Company has accrued payroll and payroll taxes in connection with salaries paid and accrued to four officers of the Company which includes $100,000 accrued for the CEO, and $12,500 accrued for executive management.

Loan Payable

Loan Payable	3 Months Ended
	Mar. 31, 2021
Debt Disclosure [Abstract]
Loan Payable	NOTE 7 – LOAN PAYABLE March 31, 2021 December 31, 2020 Loan payable at 8%, matures December 31, 2021 * $ 850,000 $ 850,000 Loan payable at 1%, matures June 11, 2021 * 100,000 100,000 Total 950,000 950,000 Less: short term loans 950,000 — Total long-term loans $ — $ 950,000 * - unsecured note Total interest expense on notes payable, amounted to $16,767 and $12,230 for the three months ended March 31, 2021 and 2020, respectively. Accrued interest related to these notes was $144,592 and $127,825 as of March 31, 2021 and December 31, 2020, respectively.

Loan Payable - Related Party

Loan Payable - Related Party	3 Months Ended
	Mar. 31, 2021
Debt Disclosure [Abstract]
Loan Payable - Related Party	NOTE 8 – LOAN PAYABLE – RELATED PARTY Prior to the share exchange agreement, the Company borrowed $25,822 and issued a promissory note with a maturity date of March 31, 2020 which was later extended to March 31, 2022. Additionally, the note holder advanced the Company $16,270 for working capital, for a total of $42,092 – also see Note 16. The loans represent working capital advances from shareholders, bear interest at 0.5%, and grant a security interest in the Company’s assets as collateral. In March 2018, this note was amended, and the original note holder assigned the note to Kettner Investments, LLC, a significant shareholder. The note is now non-interest bearing. Accrued interest related to this note is $226 as of March 31, 2021 and December 31, 2020, respectively.

Capital Lease Obligations

Capital Lease Obligations	3 Months Ended
	Mar. 31, 2021
Debt Disclosure [Abstract]
Capital Lease Obligations	NOTE 9 – CAPITAL LEASE OBLIGATIONS In September 2019, the Company entered into a lease agreement with Thermo Fisher Scientific to acquire equipment with 48 monthly payments of $941, payable through September 1, 2023, with an effective interest rate of 12% per annum. The outstanding balance of this capital lease was $25,739, secured by equipment with carrying value of $29,221, as of March 31, 2021. In March 2021, the Company entered into another lease agreement with Thermo Fisher Scientific to acquire equipment with 36 monthly payments of $699, payable through February 29, 2024, with an effective interest rate of 13% per annum. The outstanding balance of this capital lease was $16,537, secured by equipment with carrying value of $24,226, as of March 31, 2021.

Convertible Notes Payable

Convertible Notes Payable	3 Months Ended
	Mar. 31, 2021
Investments, Debt and Equity Securities [Abstract]
Convertible Notes Payable	NOTE 10 – CONVERTIBLE NOTES PAYABLE Prior to the Share Exchange, the Company issued a convertible note to an investor, face value of $500,000, in exchange for $500,000 in cash. The note is unsecured, bears interest at the rate of 3% per annum and matures on February 16, 2030. The note is convertible into common stock of the Company at $0.10 per share at any time at the option of the holder, subject to a 4.9% blocking provision which prohibits the holder from converting into common stock of the Company if such conversion results in the holder owning greater than 4.9% of the outstanding common stock of the Company after giving effect to such conversion. On September 26, 2019, the Company issued 1,500,000 shares of common stock for the conversion of $123,627 convertible notes payable and $26,373 of related accrued interest. The outstanding balance on this convertible note after the conversion was $376,373. In December 2019, the Company entered into a Securities Purchase Agreement with an investor pursuant to which the Company agreed to sell to the investor a $100,000 convertible note bearing interest at 8% per annum (the “Note”). The Note matures two years from the date of issuance. The Note is convertible at the option of the holder at any time into shares of the Company’s common stock at an effective conversion price of 75% of the average closing price of the Company’s common stock on the fifteen days prior to conversion. The Company may not prepay this Note within the first six months. If, after the first six months until the maturity of the Note the Company: (a) elects to repay the Note, it must do so at a premium of one hundred and twenty five percent (125%) of the face amount of the Note, together with all unpaid and accrued interest to the date of repayment. (b) elects to involuntarily exercise conversion of this Note to the Holder, the Company must provide written notice to the Holder along with an executed copy of the Company’s Notice of Conversion, specifying that the Note shall be converted into shares of the Company’s Common Stock based upon at an effective conversion price of 75% of the average closing price of the Company’s common stock on the fifteen days prior to conversion. The embedded conversion feature of this Note was deemed to require bifurcation and liability classification, at fair value. Pursuant to the Securities Purchase Agreement, the Company also sold warrants to the investors to purchase up to an aggregate of 100,000 shares of common stock. The fair value of the derivative liability and warrants as of the date of issuance was in excess of the Note (see Note 12) resulting in full discount of the Note. On March 12, 2020, the Company entered into securities purchase agreements with two different accredited investors (each an “Investor”, and together the “Investors”) pursuant to which each Investor purchased an 8% unsecured convertible promissory note (each a “8% Note”, and together the “8% Notes”) from the Company. The terms and conditions of each of the 8% Notes are substantially the same. Each 8% Note has a principal amount of $105,000 less a $5,000 original issue discount for a purchase price of $100,000, with a maturity date of March 12, 2021. This note is in default as of March 12, 2021, which may trigger cross defaults on other notes. The Company is in negotiations to extend the maturity date of the Note. All principal amounts and the interest thereon are convertible into shares of the Company’s common stock at the option of each Investor, after six (6) months from the date of the 8% Notes. These 8% Notes have a variable conversion price and the Company recorded embedded derivative liabilities. The fair value of the derivative liability and warrants as of the date of issuance was in excess of the 8% Note (see Note 12) resulting in full discount of the 8% Note. During the three ended March 31, 2021, the Company issued 988,069 shares of common stock for the conversion of $85,000 convertible notes payable and $4,731 of related accrued interest. The outstanding balance on these convertible notes after the conversion was $14,000. On June 8, 2020, the Company entered into a securities purchase agreement, dated as of June 2, 2020 (the “Purchase Agreement”), with an accredited investor pursuant to which the investor purchased a 12% unsecured convertible promissory note (the “12% Note”) from the Company. The 12% Note has a principal amount of $165,000 less a $9,000 original issue discount (“OID”) for a purchase price of $156,000, of which $52,000 was paid on June 8, 2020 less $3,100 in transaction fees (the “First Tranche”). The 12% Note matures 12 months from the effective date of each tranche. All principal amounts and the interest thereon are convertible into shares of the Company’s common stock at the option of the Investor, after six (6) months from the date of the 12% Note. All closings occurred following the satisfaction of customary closing conditions. The 12% Note is convertible at the option of the holder at any time into shares of the Company’s common stock at an effective conversion price of the lesser of (i) 68% multiplied by the lowest Trading Price (representing a discount rate of 32%) during the previous fifteen (15) trading day period ending on the latest complete trading day prior to the date of the 12% Note or (ii) the Variable Conversion Price. In connection with the Purchase Agreement and the 12% Note, the Company issued a common stock purchase warrant to purchase 36,666 shares of the Company’s common stock at $0.75 per share (the “Warrant”) which may be exercised by cashless exercise, exercisable for a period of three years. The 12% Note has a variable conversion price and the Company recorded embedded derivative liabilities. The fair value of the derivative liability and warrants as of the date of issuance was in excess of the 12% Note (see Note 13) resulting in full discount of the 12% Note. On June 23, 2020, the Company entered into a securities purchase agreement, dated as of June 19, 2020, with an accredited investor pursuant to which the investor purchased a 12% convertible promissory note in the principal amount of $150,000, less $20,750 in transaction-related, broker, legal and due diligence expenses. The note matures on June 19, 2021. Principal payments on the note shall be made in six (6) installments, each in the amount of $25,000, starting on December 19, 2020, and continuing thereafter each thirty (30) days for five (5) months. Notwithstanding the foregoing, the final payment of principal and accrued and unpaid interest shall be due on the June 19, 2021. The investor is entitled to, at its option, convert all or any amount of the principal amount and any accrued but unpaid interest of the note into shares of the Company’s common stock, at any time upon an event of default, at a conversion price for each share of common stock equal to the lesser of (i) the lowest trading price during the previous five (5) trading day period ending on the latest complete trading day prior to the date of the note, or (ii) the Variable Conversion Price, subject to certain equitable adjustments. Furthermore, in connection with the securities purchase agreement and the note, the Company issued two common stock purchase warrants each to purchase 115,385 shares of the Company’s common stock at $1.30 per share which may be exercised by cashless exercise, exercisable for a period of five years. One of the warrants only becomes exercisable upon default of the note. During the first quarter of 2021, the anti-dilution clause was triggered and the exercise price was reset to $0.09 resulting in the number of warrants to be increased to 1,696,838. The note has a variable conversion price and the Company recorded embedded derivative liabilities. The fair value of the derivative liability and warrants as of the date of issuance was in excess of the note (see Note 13) resulting in full discount of the note. Total interest expense on convertible notes payable, inclusive of amortization of debt discount of $81,694 and $29,589, amounted to $94,194 and $32,522 for the three months ended March 31, 2021 and 2020, respectively. Total accrued interest on convertible notes payable, as of March 31, 2021 and December 31, 2020, was $41,367 and $39,993, respectively.

Convertible Notes Payable - Rel

Convertible Notes Payable - Related Party	3 Months Ended
	Mar. 31, 2021
SEC Schedule, 12-15, Insurance Companies, Summary of Investments, Other than Investments in Related Parties [Abstract]
Convertible Notes Payable - Related Party	NOTE 11 – CONVERTIBLE NOTES PAYABLE – RELATED PARTY In January 2020, the Company sold an additional $100,000, to Kettner Investments, LLC, a significant shareholder, under the Note and sold warrants to purchase up to an aggregate of 100,000 shares of common stock under the Securities Purchase Agreement. The fair value of the derivative liability and warrants as of the date of issuance was in excess of the Note (see Note 13) resulting in full discount of the Note. In February 2020, the Company sold an additional $50,000, to the CEO of MJNA, a significant shareholder, under the Note and sold warrants to purchase up to an aggregate of 50,000 shares of common stock under the Securities Purchase Agreement. The fair value of the derivative liability and warrants as of the date of issuance was in excess of the Note (see Note 13) resulting in full discount of the Note. Total interest expense on convertible notes payable – related party, inclusive of amortization of debt discount of $18,493 and $14,521, amounted to $21,493 and $16,698 for the three months ended March 31, 2021 and 2020, respectively. Total accrued interest on convertible notes payable – related party, as of March 31, 2021 and December 31, 2020, was $14,178 and $11,178, respectively. The following is a schedule by year of future debt payments at March 31, 2021. Year Ending December 31, Loan payable Loan payable - related party Convertible notes payable Convertible notes payable - related party Total 2021 – remainder of the year $ 950,000 $ 42,092 $ 319,000 $ 100,000 $ 1,411,092 2022 — — — 50,000 50,000 2023 — — — — — 2024 — — — — — 2025 — — — — — Thereafter — — $ 376,373 — 376,373 Total $ 950,000 $ 42,092 $ 695,373 $ 150,000 $ 1,837,465

Patent Purchase Liability

Patent Purchase Liability	3 Months Ended
	Mar. 31, 2021
Notes To Financial Statements Abstract
Patent Purchase Liability	NOTE 12 – PATENT PURCHASE LIABILITY On December 17, 2020, the Company entered into an Intellectual Property Rights Purchase and Transfer Agreement (the “IP Purchase Agreement”) by and between Advanced Neural Dynamics (“AND”), Fox Chase, Dr. Douglas Brenneman (“Brenneman”) and the Company to acquire the IP Rights and concurrently entered into a Pharmaceutical Royalty Agreement with AND and Fox Chase. Pursuant to the IP Purchase Agreement, the Company acquired the IP Assets for a $570,000 aggregate purchase price payable in restricted common stock of the Company to Fox Chase, Brenneman and AND, payable as follows: • 1,000,000 shares of restricted common stock of the Company were issued to Fox Chase at a price per share of $0.27 for an aggregate of $270,000; and • $300,000 in common stock will be issued to AND/Brenneman in five annual installments which shall be calculated as $60,000 divided by the average ten day closing price prior to each installment date with the initial installment date occurring on January 5, 2021; provided, however, that for the initial installment issuance price only, the price per share shall not be below $0.30 or above $0.60 per share. In addition, AND/Brenneman shall receive cash payments of $15,000 annually, payable in quarterly installments to offset against tax payments, netted out against actual tax costs incurred. In the event such payments are not made, there will be a 10% penalty assessed on said late tax offset payment. The liabilities from the IP purchase agreement are recognized at the commencement date based on the present value of remaining payments over the payment term using the Company’s secured incremental borrowing rates or implicit rates, when readily determinable. The Company’s IP purchase agreement does not provide an implicit rate that can readily be determined. Therefore, the Company uses an 8% discount rate based on our incremental borrowing rate, which is determined using the average interest rate of our long-term debt as of December 17, 2020. Maturity of Patent Purchase Liability Year Ending December 31, 2021 - remainder of the year $ 15,000 2022 75,000 2023 75,000 2024 75,000 2025 75,000 Total undiscounted payments 315,000 Less: Imputed interest 57,039 Present value of Patent Purchase liabilities $ 257,961

Derivative Liabilities

Derivative Liabilities	3 Months Ended
	Mar. 31, 2021
Notes To Financial Statements Abstract
Derivative Liabilities	NOTE 13 – DERIVATIVE LIABILITIES The Company issued debts that consist of the issuance of convertible notes with variable conversion provisions. In addition, the Company issued warrants with variable conversion provisions. The conversion terms of the convertible notes and warrants are variable based on certain factors, such as the future price of the Company’s common stock. The number of shares of common stock to be issued is based on the future price of the Company’s common stock. The number of shares of common stock issuable upon conversion of the promissory note is indeterminate. Pursuant to ASC 815-15 Embedded Derivatives, the fair values of the variable conversion option and warrants and shares to be issued were recorded as derivative liabilities on the issuance date. Based on the various convertible notes described in Note 10 and 11, the fair value of applicable derivative liabilities on notes, warrants and change in fair value of derivative liability are as follows for the three months ended March 31, 2021: Derivative Liability - Convertible Notes Derivative Liability - Warrants Total Balance as of December 31, 2020 $ 153,140 $ 163,049 $ 316,189 Additions during the period — — — Change in fair value 72,116 38,100 110,216 Change due to exercise / redemptions (68,072 ) — (68,072 ) Balance as of March 31, 2021 $ 157,184 $ 201,149 $ 358,333 The fair value of the derivative liability – convertible notes is estimated using a Monte Carlo pricing model with the following assumptions: Market value of common stock $0.11 – 0.35 Expected volatility 82% - 103.1% Expected term (in years) 0.17 – 0.84 Risk-free interest rate 0.00 % The fair value of the derivative liability – warrants is estimated using a Monte Carlo pricing model with the following assumptions: Market value of common stock $0.11 – 0.11 Expected volatility 99.9% - 114.3% Expected term (in years) 1.73 – 4.22 Risk-free interest rate 0.00 %

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	NOTE 14 – COMMITMENTS AND CONTINGENCIES Legal Proceedings From time to time the Company may get involved in legal proceedings arising in the ordinary course of business. Other than as set forth in “Legal Proceedings” in Part II below, the Company believes there is no litigation pending that could have, individually or in the aggregate, a material adverse effect on its results of operations or financial condition. Occupancy Leases On April 1, 2014, the Company entered into a one year lease arrangement for office space, with the option to renew the lease annually. The lease has been renewed through April 2022. The monthly rent payment is $5,600 and the security deposit is $15,000. On September 15, 2015, we entered into a one year lease arrangement for additional office space, the lease has been renewed is currently scheduled to expire on September 30, 2021. The monthly rent payment is $359, and we provided a security deposit of $183. On July 1, 2018, we entered into a one year lease arrangement for additional office space, with the option to renew the lease annually. On September 1, 2018, we subleased this office space to a third party. The subleasee will pay 50% of the rent until expiration of lease on June 30, 2021. The monthly rent payment is $2,723, and we provided a security deposit of $2,121. Royalties On December 17, 2020, the Company entered into an Intellectual Property Rights Purchase and Transfer Agreement by and between AND, Fox Chase, Brenneman and the Company to acquire the IP Rights and concurrently entered into the “Royalty Agreement with AND and Fox Chase. Pursuant to the Royalty Agreement, the following royalties and license fees are payable to Fox Chase and AND as well: • 1% royalties on net sales up to $500,000 per year per participant (for an aggregate maximum of 2% and up to $1,000,000); • 1% upfront sublicense fees per participant; and • 1% reversion rights to each participant (for 2% aggregate), which rights include future milestone payments.

Stockholders' Equity (Deficit)

Stockholders' Equity (Deficit)	3 Months Ended
	Mar. 31, 2021
Equity [Abstract]
Stockholders' Equity	NOTE 15 – STOCKHOLDERS’ DEFICIT Series A Preferred Stock Effective May 3, 2018, the Company’s Board of Directors authorized and designated 75 shares of the Company’s Preferred Stock as Series A Preferred Stock. Each share of the Series A Preferred Stock is entitled to a liquidation preference of $1,000 per share and is convertible into 1,000 shares of the Company’s common stock. The holders of a majority of the Series A Preferred Stock are entitled to elect up to four (4) directors to the Company’s board of directors and have preferential rights in regard to the election of Series A directors. In all other voting matters, the holders of Series A Preferred Stock are entitled to cast 1,000 votes per share. Series B Preferred Stock Effective May 3, 2018, the Company’s Board of Directors authorized and designated 75 shares of the Company’s Preferred Stock as Series B Preferred Stock. Each share of the Series B Preferred Stock is entitled to a liquidation preference of $1,000 per share and is convertible into 1,000 shares of the Company’s common stock. The holders of a majority of the Series B Preferred Stock are entitled to elect up to three (3) directors to the Company’s board of directors and have preferential rights in regard to the election of Series B directors. In all other voting matters, the holders of Series B Preferred Stock are entitled to cast 1,000 votes per share. Common Stock The Company is authorized to issue 200,000,000 shares of common stock, par value of $0.0001 per share. All common stock shares have equal voting rights, are non-assessable and have one vote per share. Voting rights are not cumulative and, therefore, the holders of more than 50% of the common stock could, if they choose to do so, elect all of the directors of the Company, subject to the rights of the preferred stockholders. Equity Purchase Agreement with Cross & Company On September 18, 2020, the Company entered into an Equity Purchase Agreement with Cross and Company. We have the right to “put,” or sell, up to 8,108,108 shares of our common stock to Cross. Unless terminated earlier, Cross’s purchase commitment will automatically terminate on the earlier of the date on which Cross shall have purchased shares pursuant to the Equity Purchase Agreement for an aggregate purchase price of $6,000,000 or September 18, 2023. The purchase price per share is calculated at a fifteen percent discount of the lowest trading price of the Company’s common stock during the ten days after Cross and Co. receives the shares. On January 4, 2021, the Company issued 109,098 shares of common stock for the conversion of $10,000 convertible notes payable and $272 of related accrued interest at $0.09 per share. On January 12, 2021, the Company issued 175,000 shares of common stock at the price of $0.18 per share in exchange for a settlement of accrued expenses. On January 13, 2021, the Company issued 117,609 shares of common stock for the conversion of $10,000 convertible notes payable and $97 of related accrued interest On January 15, 2021, the Company issued 29,167 shares of common stock at $0.23 a share, to a consultant for business development services. On January 15, 2021, the Company issued 313,972 shares of common stock at the price of $0.19 per share for the purchase of intellectual property based on a five year installment sale. This compensation is included in research and development on the consolidated statement of operations. The issuance was an error and was intended, as per agreement to be 200,000 shares at the floor price of $.30 per share. The Company and the recipient have discussed the cancellation of 113,972 shares which will occur in the second quarter of 2021. On January 28, 2021, the Company sold 388,583 shares of common stock at the purchase price of $0.13 per share for a total purchase price of $51,410. On February 1, 2021, the Company issued 517,674 shares of common stock for the conversion of $45,000 convertible notes payable and $162 of related accrued interest On February 10, 2021, the Company issued 243,688 shares of common stock for the conversion of $20,000 convertible notes payable and $4,200 of related accrued interest On February 10, 2021, the Company issued 697,714 shares of common stock in exchange of cash at $0.17 per share for a total purchase price of $121,577. On February 10, 2021, the Company issued 3,500,000 shares of common stock in exchange of cash at $0.10 per share for a total purchase price of $350,000. On February 22, 2021, the Company issued 715,893 shares of common stock in exchange of cash at $0.16 per share for a total purchase price of $115,617. On February 26, 2021, the Company issued 1,050,045 shares of common stock in exchange of cash at $0.09 per share for a total purchase price of $90,146. O n March 2, 2021, the Company issued 520,000 shares of common stock at the price of $0.10 per share in exchange for a settlement of accrued expenses. On March 4, 2021, the Company issued 320,833 shares of common stock at $0.23 a share, to a consultant for business development services. On March 12, 2021, the Company issued its CEO 692,308 shares of common stock at $0.13 a share in lieu of $90,000 of deferred salary. On March 25, 2021, the Company issued 657,394 shares of common stock in exchange of cash at $0.14 per share for a total purchase price of $56,437. Stock Options On May 4, 2020, the Company granted options to purchase 6,050,000 shares of common stock at a price of $0.57 per share to certain directors and employees of the Company (including our named executive officers) and are exercisable for ten years. One quarter of these options vest on the grant day, and the remainder of the options vest equally over thirty six (36) months starting January 1, 2020. These options were valued at $3,152,050 using a Black-Scholes Options Pricing Model. On May 18, 2020, the Company granted options to purchase 75,000 shares of common stock at a price of $0.51 per share to a consultant and are exercisable for ten years. One quarter of these options vest on the grant day, and the remainder of the options vest equally over twelve (12) months. These options were valued at $34,260 using a Black-Scholes Options Pricing Model. On September 14, 2020 and December 24, 2020, the Company granted options to purchase 250,000 shares of common stock, respectively, at a price of $0.84 and $0.20 per share, respectively, to a consultant and are exercisable for ten years. One quarter of these options vest on the grant day, and the remainder of the options vest equally over twelve (12) months. These options were valued at $180,950 using a Black-Scholes Options Pricing Model. On September 23, 2020, the Company granted options to purchase 200,000 shares of common stock at a price of $0.80 per share to a consultant, who is a related party, and are exercisable for ten years. One quarter of these options vest on the grant day, and the remainder of the options vest equally over twenty four (24) months. These options were valued at $109,060 using a Black-Scholes Options Pricing Model. On December 28, 2020, the Company granted options to purchase 200,000 shares of common stock at a price of $0.18 per share to a consultant and are exercisable for ten years. One quarter of these options vest on the grant day, and the remainder of the options vest equally over twelve (12) months. These options were valued at $26,720 using a Black-Scholes Options Pricing Model. On March 12, 2021, the Company granted options to purchase 7,350,000 shares of common stock at a price of $0.13 per share to certain directors and employees of the Company (including our named executive officers) and are exercisable for ten years. One quarter of these options vested on the grant day, and the remainder of the options vest equally over thirty-six months starting March 12, 2021. These options were valued at $732,795 using a Black-Scholes Options Pricing Model. On March 12, 2021, the Company granted options to purchase 200,000 shares of common stock at a price of $0.13 per share to a certain member of the Company’s corporate advisory board, as governed under agreement. One quarter of these options vested on the grant day, and the remainder of the options vest equally over twenty four months thereafter. These options were valued at $19,940 using a Black-Scholes Options Pricing Model. The remaining expense outstanding through March 12, 2024 is $2,079,225. For the three months ended March 31, 2021 and 2020, the Company recorded $382,473 and $0, respectively, as stock based compensation which is included in the general and administrative expenses in the condensed consolidated statement of operations and $71,477 and $0, respectively, as research and development expense. The fair value of the options is estimated using a Black-Scholes Options Pricing Model with the following assumptions: Market value of common stock on issuance date $0.13 – 0.84 Exercise price $0.13 – 2.00 Expected volatility 86 – 138% Expected term (in years) 5.50 – 6.50 Risk-free interest rate 0.64 – 1.73% Expected dividend yields — On August 14, 2019, the Board authorized the Company’s 2019 Equity Incentive Plan (the “2019 Plan”) in order to facilitate the grant of cash and equity incentives to directors, employees (including our named executive officers) and consultants of our company and certain of its affiliates and to enable our company and certain of its affiliates to obtain and retain services of these individuals, which is essential to our long-term success. Our 2019 Plan allows for the grant of a variety of equity vehicles to provide flexibility in implementing equity awards, including incentive stock options, non-qualified stock options, restricted stock grants, unrestricted stock grants and restricted stock units. There were initially 7,500,000 shares of Company common stock authorized for issuance under our 2019 Plan. On May 4, 2020, the Company amended its 2019 Plan to increase the number of shares of Company common stock authorized for issuance thereunder to 11,500,000 shares. On March 12, 2021, the Company executed a second amendment to the 2019 Plan to (i) replace all references to “Kannalife, Inc.,” the Company’s former name, to “Neuropathix, Inc.,” and (ii) increase the number of shares of Company common stock authorized for issuance thereunder 20,000,000 shares (the “Second Plan Amendment”). The Second Plan Amendment was approved by the Company’s Board of Directors on March 12, 2021. The Second Plan Amendment remains subject to shareholder approval, which the Company shall undertake to obtain as soon as reasonably practicable, but in no event later than one year from the amendment date. In the event that the Company does not obtain the requisite shareholder approval of the Second Plan Amendment within one year, the Second Plan Amendment shall not be effective. As of March 31, 2021, there were 13,000,000 shares of Company common stock issued and outstanding under the 2019 Plan, as amended. The following is a summary of outstanding and exercisable options: Numbers of Options Weighted Avg Exercise Price Weighted Avg Remaining Years Outstanding as of December 31,2020 7,125,000 $ 0.58 9.30 Granted 7,550,000 0.13 9.95 Exercised — — — Forfeited — — — Expired — — — Outstanding as of March 31,2021 14,675,000 $ 0.35 9.52 Outstanding as of March 31, 2021, vested 5,898,177 $ 0.45 9.28 Warrants In January and February 2020, the Company entered into a Securities Purchase Agreement with investors pursuant to which the Company agreed to sell the investors a $100,000 and $50,000 convertible note bearing interest at 8% per annum, respectively. The Company also sold warrants to the investors to purchase up to an aggregate of 100,000 and 50,000 shares of common stock, respectively, with an exercise term of three (3) years, at a per share purchase price of one hundred twenty five percent (125%) of the voluntary or involuntary conversion price of the Company’s 8% convertible note. The warrants were deemed as a derivative liability and was recorded as a debt discount at date of issuance. See Note 10. On June 8, 2020, the Company entered into a Securities Purchase Agreement, dated as of June 2, 2020 (the “Purchase Agreement”) with an accredited investor pursuant to which the investor purchased a 12% unsecured convertible promissory note (the “12% Note”) from the Company. In connection with the Purchase Agreement and the 12% Note, the Company issued a common stock purchase warrant to purchase 36,666 shares of the Company’s common stock at $0.75 per share which may be exercised by cashless exercise, exercisable for a period of three years. The warrants were deemed as a derivative liability and was recorded as a debt discount at date of issuance. See Note 10. On June 23, 2020, the Company entered into a Securities Purchase Agreement, dated as of June 19, 2020 with an accredited investor pursuant to which the Investor purchased a 12% convertible promissory note from the Company. In connection with the securities purchase agreement and the note, the Company issued two common stock purchase warrants each to purchase 115,385 shares of the Company’s common stock at $1.30 per share which may be exercised by cashless exercise, exercisable for a period of five years. One of the warrants is to be issued only in the case of default on the note. During the first quarter of 2021, the anti-dilution clause was triggered and the exercise price was reset to $0.09 resulting in the number of warrants to be increased to 1,696,838. The warrants were deemed as a derivative liability and was recorded as a debt discount at date of issuance. See Note 10. On February 10, 2021, the Company entered into a letter agreement with Lyons Capital, pursuant to which the Company agreed to issue and sell 3,500,000 shares of the Company’s common stock, par value $0.0001 per share, and two warrants to purchase an aggregate of 3,500,000 additional shares of Common Stock, the terms of such warrants are further discussed below, for an aggregate purchase price of $1,207,500. The first warrant grants Lyons Capital the right to purchase up to 1,750,000 shares of common stock at an exercise price of $0.22 per share. The second warrant grants Lyons Capital the right to purchase up to an additional 1,750,000 shares of common stock at an exercise price of $0.27 per share. The warrants are exercisable immediately, will expire five years from the date of issuance, and contain customary provisions allowing for adjustment to the exercise price and number of shares of common stock issuable upon exercise in the event of any stock dividend, recapitalization, reorganization, reclassification, or similar transaction. Lyons Capital has the right to exercise the warrants at any time; provided, however, that subject to limited exceptions, Lyons Capital may not exercise any portion of the warrants if Lyons Capital, together with any of its affiliates, would beneficially own in excess of 4.99% of the number of shares of the Company’s common stock outstanding immediately after giving effect to such exercise. The following is a summary of outstanding and exercisable warrants: Number of Shares Weighted Average Exercise Price Balance at December 31, 2020 1,289,343 $ 0.18 Issued 4,194,161 0.25 Expired — — Balance at March 31, 2021 5,483,504 $ 0.20 At March 31, 2021, 5,483,504 warrants for common stock were exercisable and the intrinsic value of these warrants was $33,258 and the weighted average remaining contractual life for warrants outstanding was 4.51 years.

Related Party Transactions

Related Party Transactions	3 Months Ended
	Mar. 31, 2021
Related Party Transactions [Abstract]
Related Party Transactions	NOTE 16 – RELATED PARTY TRANSACTIONS The Company’s Chief Executive Officer (“CEO”) shares the use of the leased office space for personal living quarters. The CEO reimburses the Company for 50% of the monthly rent, or $2,800 per month. As of March 31, 2021, the Company owes the CEO $100,000 for accrued compensation and $28,415 for expenses incurred on behalf of the Company. During the three months ended March 31, 2021, the Company repaid $40,000 to its CEO in exchange for the discharge of a portion of his accrued expenses. On March 12, 2021, the Company issued its CEO 692,308 shares of common stock at $0.13 a share in lieu of $90,000 of accrued compensation. See Notes 8, 11 and 14 for additional related party transactions.

Subsequent Events

Subsequent Events	3 Months Ended
	Mar. 31, 2021
Subsequent Events [Abstract]
Subsequent Events	NOTE 17 – SUBSEQUENT EVENTS In May 2021, the Company repaid $10,000 to its CEO in exchange for the discharge of a portion of his accrued expenses.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2021
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States, or GAAP.
Significant risks and uncertainties	Significant Risks and Uncertainties The Company’s operations are subject to a number of factors that can affect its operating results and financial condition. Such factors include, but are not limited to: the results of clinical testing and trial activities of the Company’s products, the Company’s ability to obtain regulatory approval to market its products, competition from products manufactured and sold or being developed by other companies, the price of, and demand for, Company products, the Company’s ability to negotiate favorable licensing or other manufacturing and marketing agreements for its products, and the Company’s ability to raise capital. The Company currently has no commercially approved products and there can be no assurance that the Company’s research and development will be successfully commercialized. Developing and commercializing a product requires significant time and capital and is subject to regulatory review and approval as well as competition from other biotechnology and pharmaceutical companies. The Company operates in an environment of rapid change and is dependent upon the continued services of its employees and consultants and obtaining and protecting intellectual property. In December 2019, a novel strain of coronavirus, commonly known as COVID-19, surfaced. The spread of COVID-19 around the world in 2020 has caused significant volatility in U.S. and international markets. There is significant uncertainty around the breadth and duration of business disruptions related to COVID-19, as well as its impact on the U.S. and international economies and, as such, the Company is unable to determine if it will have a material impact to its operations. The Company’s operations as of March 31, 2021 have not been significantly affected, but may be affected in the future, by the ongoing outbreak of COVID-19 which was declared a pandemic by the World Health Organization. The ultimate disruption which may be caused by the outbreak is uncertain; however, it may result in a material adverse impact on the Company’s financial position, operations and cash flows. Possible areas that may be affected include, but are not limited to, disruption to the Company’s labor workforce, unavailability of products and supplies used in operations, and the decline in value of assets held by the Company.
Use of Estimates	Use of Estimates The preparation of consolidated financial statements and accompanying notes in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the dates of the consolidated financial statements, and the reported amounts of revenues and expenses during the periods. Actual results could differ from those estimates. Significant matters requiring the use of estimates and assumptions include, but are not necessarily limited to, establishing the fair value of marketable securities and periodically evaluating marketable securities for potential impairment, fair value of the Company’s stock, stock-based compensation, valuation of derivative liabilities and valuation allowance relating to the Company’s deferred tax assets. Management believes that its estimates and assumptions are reasonable, based on information that is available at the time they are made.
Net Loss per Share	Net Loss per Share Basic net loss per share is calculated by dividing the net loss for the period by the weighted-average number of common shares outstanding during the period. Diluted net income per share is calculated by dividing income for the period by the weighted-average number of common shares outstanding during the period, increased by potentially dilutive common shares ("dilutive securities") that were outstanding during the period. Dilutive securities include stock options and warrants granted, convertible debt, and convertible preferred stock. The weighted average number of common stock equivalents not included in diluted income per share, because the effects are anti-dilutive, was 29,446,224 and 4,898,092 for the three months ended March 31, 2021 and 2020, respectively.
Research and Development	Research and Development In accordance with FASB ASC 730, Research and Development Stock Based Compensation The Company accounts for share-based compensation in accordance with the fair value recognition provision of FASB ASC 718, Compensation – Stock Compensation (“ASC 718”), prescribes accounting and reporting standards for all share-based payment transactions in which employee services are acquired. Transactions include incurring liabilities, or issuing or offering to issue shares, options, and other equity instruments such as employee stock ownership plans and stock appreciation rights. Share-based payments to employees, including grants of employee stock options, are recognized as compensation expense, which is included in the general and administrative expense in the consolidated financial statements based on the estimated grant date fair values. That expense is recognized over the period during which an employee is required to provide services in exchange for the award, known as the requisite service period (usually the vesting period).
Recently Issued Authoritative Guidance	Recently Issued Authoritative Guidance In June 2016, the FASB issued ASU 2016-13, “Financial Instruments – Credit Losses” to improve information on credit losses for financial assets and net investment in leases that are not accounted for at fair value through net income. ASU 2016-13 replaces the current incurred loss impairment methodology with a methodology that reflects expected credit losses. In April 2019 and May 2019, the FASB issued ASU No. 2019-04, “Codification Improvements to Topic 326, Financial Instruments-Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments” and ASU No. 2019-05, “Financial Instruments-Credit Losses (Topic 326): Targeted Transition Relief” which provided additional implementation guidance on the previously issued ASU. In November 2019, the FASB issued ASU 2019-10, “Financial Instruments - Credit Loss (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842),” which defers the effective date for public filers that are considered small reporting companies (“SRC”) as defined by the Securities and Exchange Commission to fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. Since the Company is an SRC, implementation is not needed until January 1, 2023. The Company will continue to evaluate the effect of adopting ASU 2016-13 will have on the Company’s consolidated financial statements.

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	3 Months Ended
	Mar. 31, 2021
Fair Value Disclosures [Abstract]
Fair Value, Liabilities Measured on Recurring Basis	The following table presents liabilities that are measured and recognized at fair value as of March 31, 2021 and December 31, 2020, on a recurring basis: March 31, 2021 Level 1 Level 2 Level 3 Total Carrying Value Derivative liabilities — — 358,333 $ 358,333 December 31, 2020 Level 1 Level 2 Level 3 Total Carrying Value Derivative liabilities — — 316,189 $ 316,189

Accounts Payable and Accrued _2

Accounts Payable and Accrued Expenses (Tables)	3 Months Ended
	Mar. 31, 2021
Payables and Accruals [Abstract]
Accounts payable and accrued expenses	Accounts payable and accrued expenses at March 31, 2021 and December 31, 2020 consisted of the following: March 31, 2021 December 31, 2020 Accounts payable and accrued expenses $ 339,961 $ 538,527 Accrued interest 210,314 182,781 Totals $ 550,275 $ 721,308

Payroll and Related Liabiliti_2

Payroll and Related Liabilities (Tables)	3 Months Ended
	Mar. 31, 2021
Payables and Accruals [Abstract]
Schedule of Payroll and Related Liabilities	Payroll and related liabilities at March 31, 2021 and December 31, 2020 consisted of the following: March 31, 2021 December 31, 2020 Payroll $ 120,234 $ 149,704 Payroll taxes 243,755 229,537 Totals $ 363,989 $ 379,241

Loan Payable (Tables)

Loan Payable (Tables)	3 Months Ended
	Mar. 31, 2021
Value of notes converted
Schedule of Loans Payable	March 31, 2021 December 31, 2020 Loan payable at 8%, matures December 31, 2021 * $ 850,000 $ 850,000 Loan payable at 1%, matures June 11, 2021 * 100,000 100,000 Total 950,000 950,000 Less: short term loans 950,000 — Total long-term loans $ — $ 950,000 * - unsecured note

Convertible Notes Payable - R_2

Convertible Notes Payable - Related Party (Tables)	3 Months Ended
	Mar. 31, 2021
SEC Schedule, 12-15, Insurance Companies, Summary of Investments, Other than Investments in Related Parties [Abstract]
Schedule of future debt payments	The following is a schedule by year of future debt payments at March 31, 2021. Year Ending December 31, Loan payable Loan payable - related party Convertible notes payable Convertible notes payable - related party Total 2021 – remainder of the year $ 950,000 $ 42,092 $ 319,000 $ 100,000 $ 1,411,092 2022 — — — 50,000 50,000 2023 — — — — — 2024 — — — — — 2025 — — — — — Thereafter — — $ 376,373 — 376,373 Total $ 950,000 $ 42,092 $ 695,373 $ 150,000 $ 1,837,465

Patent Purchase Liability (Tabl

Patent Purchase Liability (Tables)	3 Months Ended
	Mar. 31, 2021
Notes To Financial Statements Abstract
Schedule of patent purchase	Therefore, the Company uses an 8% discount rate based on our incremental borrowing rate, which is determined using the average interest rate of our long-term debt as of December 17, 2020. Maturity of Patent Purchase Liability Year Ending December 31, 2021 - remainder of the year $ 15,000 2022 75,000 2023 75,000 2024 75,000 2025 75,000 Total undiscounted payments 315,000 Less: Imputed interest 57,039 Present value of Patent Purchase liabilities $ 257,961

Derivative Liabilities (Tables)

Derivative Liabilities (Tables)	3 Months Ended
	Mar. 31, 2021
Schedule of Derivative Liabilities	Based on the various convertible notes described in Note 10 and 11, the fair value of applicable derivative liabilities on notes, warrants and change in fair value of derivative liability are as follows for the three months ended March 31, 2021: Derivative Liability - Convertible Notes Derivative Liability - Warrants Total Balance as of December 31, 2020 $ 153,140 $ 163,049 $ 316,189 Additions during the period — — — Change in fair value 72,116 38,100 110,216 Change due to exercise / redemptions (68,072 ) — (68,072 ) Balance as of March 31, 2021 $ 157,184 $ 201,149 $ 358,333
Warrants
Schedule of share-based payment award, stock options, valuation assumptions	The fair value of the derivative liability – warrants is estimated using a Monte Carlo pricing model with the following assumptions: Market value of common stock $0.11 – 0.11 Expected volatility 99.9% - 114.3% Expected term (in years) 1.73 – 4.22 Risk-free interest rate 0.00 %
Convertible Notes
Schedule of share-based payment award, stock options, valuation assumptions	The fair value of the derivative liability – convertible notes is estimated using a Monte Carlo pricing model with the following assumptions: Market value of common stock $0.11 – 0.35 Expected volatility 82% - 103.1% Expected term (in years) 0.17 – 0.84 Risk-free interest rate 0.00 %

Stockholders' Equity (Deficit)

Stockholders' Equity (Deficit) (Tables)	3 Months Ended
	Mar. 31, 2021
Schedule of outstanding and exercisable options	The following is a summary of outstanding and exercisable options: Numbers of Options Weighted Avg Exercise Price Weighted Avg Remaining Years Outstanding as of December 31,2020 7,125,000 $ 0.58 9.30 Granted 7,550,000 0.13 9.95 Exercised — — — Forfeited — — — Expired — — — Outstanding as of March 31,2021 14,675,000 $ 0.35 9.52 Outstanding as of March 31, 2021, vested 5,898,177 $ 0.45 9.28
Schedule of outstanding and exercisable warrants	The following is a summary of outstanding and exercisable warrants: Number of Shares Weighted Average Exercise Price Balance at December 31, 2020 1,289,343 $ 0.18 Issued 4,194,161 0.25 Expired — — Balance at March 31, 2021 5,483,504 $ 0.20
Option [Member]
Schedule of share-based payment award, stock options, valuation assumptions	The fair value of the options is estimated using a Black-Scholes Options Pricing Model with the following assumptions: Market value of common stock on issuance date $0.13 – 0.84 Exercise price $0.13 – 2.00 Expected volatility 86 – 138% Expected term (in years) 5.50 – 6.50 Risk-free interest rate 0.64 – 1.73% Expected dividend yields —

Organization and Nature of Op_2

Organization and Nature of Operations (Details Narrative)	3 Months Ended
	Mar. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Date of Incorporation	Mar. 25, 2013

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020
Accounting Policies [Abstract]
Allowance for doubtful account	$ 0		$ 0
Weighted average number of common stock, anti-dilutive	29,446,224	4,898,092
Research and Development	$ 128,648	$ 19,727

Going Concern and Management'_2

Going Concern and Management's Liquidity Plans (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Net loss from operations	$ (1,083,837)	$ (383,834)
Accumulated deficit	$ (14,361,937)		$ (13,033,363)

Fair Value Measurements - Fair

Fair Value Measurements - Fair Value, liabilities Measured on Recurring Basis (Details) - USD ($)	Mar. 31, 2021	Dec. 31, 2020
Derivative liabilities	$ 358,333	$ 316,189
Level 1
Derivative liabilities	0	0
Level 2
Derivative liabilities	0	0
Level 3
Derivative liabilities	358,333	316,189
Total Carrying Value
Derivative liabilities	$ 358,333	$ 316,189

Accounts Payable and Accrued _3

Accounts Payable and Accrued Expenses (Details) - USD ($)	Mar. 31, 2021	Dec. 31, 2020
Payables and Accruals [Abstract]
Accounts payable and accrued expenses	$ 339,961	$ 538,527
Accrued interest	210,314	182,781
Totals	$ 550,275	$ 721,308

Payroll and Related Liabiliti_3

Payroll and Related Liabilities - Schedule Of Accrued Payroll And Payroll Taxes (Details) - USD ($)	Mar. 31, 2021	Dec. 31, 2020
Accrued Payroll And Payroll Taxes - Schedule Of Accrued Payroll And Payroll Taxes
Payroll	$ 120,234	$ 149,704
Payroll taxes	243,755	229,537
Totals	$ 363,989	$ 379,241

Payroll and Related Liabiliti_4

Payroll and Related Liabilities (Details Narrative) - USD ($)	Mar. 31, 2021	Dec. 31, 2020
Payroll taxes	$ 243,755	$ 229,537
Chief Executive Officer
Payroll taxes	100,000
Director [Member]
Payroll taxes	$ 12,500

Loan Payable - Loans payable (D

Loan Payable - Loans payable (Details) - USD ($)		3 Months Ended
		Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020
Total		$ 950,000		$ 950,000
Less: short term loans		950,000
Total long-term loans				950,000
Debt Instrument, interest rate		0.50%
Debt instrument, maturity date		Mar. 31, 2022
Loan payable One [Member]
Total	[1]	$ 850,000		850,000
Debt Instrument, interest rate		8.00%	8.00%
Debt instrument, maturity date		Dec. 31, 2021	Dec. 31, 2021
Loan payable two [Member]
Total	[1]	$ 100,000		$ 100,000
Debt Instrument, interest rate		1.00%	1.00%
Debt instrument, maturity date		Jun. 11, 2021	Jun. 11, 2021
[1]	unsecured note

Loan Payable (Details Narrative

Loan Payable (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020
Debt Disclosure [Abstract]
Interest expense	$ 16,767	$ 12,230
Accrued interest	$ 144,592		$ 127,825
Maturity date	Mar. 31, 2022

Loan Payable - Related Party (D

Loan Payable - Related Party (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2021	Dec. 31, 2020
Maturity date	Mar. 31, 2022
Interest rate	0.50%
Advanced from related party	$ 28,415	$ 55,258
Related Party Promissory Note
Note payable, related party	25,822
Accrued interest, related party note	226	$ 226
Advanced from related party	16,270
Working capital	$ 42,092

Capital Lease Obligations (Deta

Capital Lease Obligations (Details Narrative) - Thermo Fisher Scientific - USD ($)	1 Months Ended
	Mar. 31, 2021	Sep. 30, 2019
Effective interest rate	12.00%
Frequency period		P48M
Monthly payment		$ 941
Capital Lease Obligations	$ 25,739
Equipment with carrying value	$ 29,221
Frequency period	P36M
Monthly payment	$ 699
Capital Lease Obligations	16,537
Equipment with carrying value	$ 24,226

Convertible Notes Payable (Deta

Convertible Notes Payable (Details Narrative) - USD ($)	Jan. 14, 2021	Jun. 08, 2020	Mar. 12, 2020	Feb. 27, 2021	Feb. 10, 2021	Jan. 28, 2021	Jun. 23, 2020	Feb. 29, 2020	Jan. 31, 2020	Dec. 31, 2019	Feb. 26, 2021	Feb. 22, 2021	Mar. 31, 2021	Mar. 25, 2021	Mar. 31, 2020	Dec. 31, 2020	Sep. 26, 2019	Jul. 24, 2015
Convertible debt													$ 88,493			$ 0
Debt discount													$ 61,507
Common stock issued													87,978,445			77,670,908
Number of warrants sold	258,559			388,583	697,714	388,583					1,050,045	715,893		657,394
Proceeds from sale of warrants						$ 51,410								$ 56,437
Interest rate													0.50%
Amortization of debt discount													$ 100,187		$ 44,109
Securities Purchase Agreement [Member]
Number of warrants sold		36,666					115,385	50,000	100,000	100,000			1,696,838
Proceeds from sale of warrants								$ 50,000	$ 100,000	$ 100,000
Interest rate		12.00%					12.00%	8.00%	8.00%	8.00%
Convertible Debt
Principal amount																		$ 500,000
Convertible debt																		$ 500,000
Maturity date																		Feb. 16, 2030
Interest rate																		3.00%
Convertible price per share																		$ 0.10
Common stock issued																	1,500,000
Value of notes converted																	$ 123,627
Accrued interest													$ 41,367			$ 39,993	$ 26,373
Interest expense													94,194		32,522
Amortization of debt discount													81,694		$ 29,589
8% Notes
Principal amount			$ 105,000
Convertible debt													$ 14,000
Maturity date			Mar. 12, 2021
Interest rate			8.00%
Debt discount			$ 5,000
Purchase price			$ 100,000
Debt conversion, description			The Note is convertible at the option of the holder at any time into shares of the Company’s common stock at an effective conversion price of the lesser of (i) $0.75 or (ii) 68% multiplied by the average of the two lowest trading closing prices of the Company’s common stock on the fifteen days before the issue date of this note or (ii) 68% multiplied by the average of the two lowest trading closing prices of the Company’s common stock on the fifteen days prior to conversion.
Common stock issued													988,069
Value of notes converted													$ 85,000
Accrued interest													$ 4,731
12% Note
Principal amount		$ 165,000
Interest rate		12.00%
Debt discount		$ 9,000
Purchase price		156,000
Repayment of related party debt		$ 52,000
Debt conversion, description		All principal amounts and the interest thereon are convertible into shares of the Company’s common stock at the option of the Investor, after six (6) months from the date of the 12% Note. All closings occurred following the satisfaction of customary closing conditions. The 12% Note is convertible at the option of the holder at any time into shares of the Company’s common stock at an effective conversion price of the lesser of (i) 68% multiplied by the lowest Trading Price (representing a discount rate of 32%) during the previous fifteen (15) trading day period ending on the latest complete trading day prior to the date of the 12% Note or (ii) the Variable Conversion Price.
Warrants per share value		$ 0.75
Transaction fees		$ 3,100
Warrants issued		36,666
12% convertible promissory note
Principal amount							$ 150,000
Maturity date							Jun. 19, 2021
Interest rate							12.00%
Debt discount							$ 20,750
Warrants per share value							$ 1.30						$ 0.15
Number of warrants sold																1,696,838
Warrants issued							115,385
Periodic payment							$ 25,000

Convertible Notes Payable - R_3

Convertible Notes Payable - Related Party (Details)	Mar. 31, 2021USD ($)
2021 - remainder of the year	$ 1,411,092
2022	50,000
2023	0
2024	0
2025	0
Thereafter	376,373
Total	1,837,465
Loans Payable [Member]
2021 - remainder of the year	950,000
2022	0
2023	0
2024	0
2025	0
Thereafter	0
Total	950,000
Loan payable - related party [Member]
2021 - remainder of the year	42,092
2022	0
2023	0
2024	0
2025	0
Thereafter	0
Total	42,092
Convertible notes payable [Member]
2021 - remainder of the year	319,000
2022	0
2023	0
2024	0
2025	0
Thereafter	376,373
Total	695,373
Convertible Notes Payable Related Party [Member]
2021 - remainder of the year	100,000
2022	50,000
2023	0
2024	0
2025	0
Thereafter	0
Total	$ 150,000

Convertible Notes Payable - R_4

Convertible Notes Payable - Related Party (Details Narrative) - USD ($)	Jan. 14, 2021	Jun. 08, 2020	Feb. 27, 2021	Feb. 10, 2021	Jan. 28, 2021	Jun. 23, 2020	Feb. 29, 2020	Jan. 31, 2020	Dec. 31, 2019	Feb. 26, 2021	Feb. 22, 2021	Mar. 31, 2021	Mar. 25, 2021	Mar. 31, 2020	Dec. 31, 2020
Number of warrants sold	258,559		388,583	697,714	388,583					1,050,045	715,893		657,394
Proceeds from sale of warrants					$ 51,410								$ 56,437
Amortization of debt discount												$ 100,187		$ 44,109
Convertible Notes Payable Related Party [Member]
Interest expense												21,493		16,698
Amortization of debt discount												18,493		$ 14,521
Accrued interest												$ 14,178			$ 11,178
Securities Purchase Agreement [Member]
Number of warrants sold		36,666				115,385	50,000	100,000	100,000			1,696,838
Proceeds from sale of warrants							$ 50,000	$ 100,000	$ 100,000
Securities Purchase Agreement [Member] | Kettner Investments
Number of warrants sold								100,000
Proceeds from sale of warrants								$ 100,000
Securities Purchase Agreement [Member] | Chief Executive Officer
Number of warrants sold							50,000
Proceeds from sale of warrants							$ 50,000

Patent Purchase Liability - Mat

Patent Purchase Liability - Maturity of Patent Purchase Liability (Details)	Mar. 31, 2021USD ($)
Commitments and Contingencies Disclosure [Abstract]
2021 - remainder of the year	$ 15,000
2022	75,000
2023	75,000
2024	75,000
2025	75,000
Total undiscounted payments	315,000
Less: imputed interest	57,039
Present value of patent purchase liabilities	$ 257,961

Patent Purchase Liability (Deta

Patent Purchase Liability (Details Narrative) - IP Purchase Agreement	1 Months Ended
	Dec. 17, 2020USD ($)$ / sharesshares
Business acquisition, consideration | $	$ 570,000
Discount rate	8.00%
Restricted Common Stock
Business acquisition, shares issued | shares	1,000,000
Business acquisition, shares issued, value | $	$ 270,000
Shares price | $ / shares	$ 0.27
Common Stock
Business acquisition, shares issued, value | $	$ 300,000
Common Stock | Minimum [Member]
Shares price | $ / shares	$ 0.30
Common Stock | Maximum [Member]
Shares price | $ / shares	$ 0.60

Derivative Liabilities - Schedu

Derivative Liabilities - Schedule of Derivative Liabilities (Details) - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Balance at beginning	$ 316,189
Additions during the period
Change in fair value	110,216	$ (291,165)
Change due to exercise / redemptions	(68,072)
Balance at end	358,333
Convertible Notes
Balance at beginning	153,140
Additions during the period
Change in fair value	72,116
Change due to exercise / redemptions	(68,072)
Balance at end	157,184
Warrants
Balance at beginning	163,049
Additions during the period
Change in fair value	38,100
Change due to exercise / redemptions
Balance at end	$ 201,149

Derivative Liabilities - Assump

Derivative Liabilities - Assumptions - Convertible notes (Details) - Convertible Notes	3 Months Ended
	Mar. 31, 2021$ / shares
Risk-free interest rate	0.00%
Minimum [Member]
Market value of common stock on issuance date	$ 0.11
Expected volatility	82.00%
Expected term (in years)	2 months 1 day
Maximum [Member]
Market value of common stock on issuance date	$ 0.35
Expected volatility	103.10%
Expected term (in years)	10 months 3 days

Derivative Liabilities - Assu_2

Derivative Liabilities - Assumptions - Warrants (Details) - Warrants	3 Months Ended
	Mar. 31, 2021$ / shares
Risk-free interest rate	0.00%
Minimum [Member]
Market value of common stock on issuance date	$ 0.11
Expected volatility	99.90%
Expected term (in years)	1 year 8 months 23 days
Maximum [Member]
Market value of common stock on issuance date	$ .11
Expected volatility	114.30%
Expected term (in years)	4 years 2 months 19 days

Commitments and Contingencies (

Commitments and Contingencies (Details Narrative) - USD ($)	Mar. 31, 2021	Dec. 31, 2020	Jul. 02, 2018	Sep. 15, 2015	Apr. 01, 2014
Security Deposit	$ 17,121	$ 17,121
Office Space
Monthly Rent			$ 2,723	$ 359	$ 5,600
Security Deposit			$ 2,121	$ 183	$ 15,000

Stockholders' Deficit - Schedul

Stockholders' Deficit - Schedule of share-based payment award, stock options, valuation assumptions (Details) - Option [Member]	3 Months Ended
	Mar. 31, 2021$ / shares
Expected dividend yields	0.00%
Minimum [Member]
Market value of common stock on issuance date	$ 0.13
Exercise price	$ 0.13
Expected volatility	86.00%
Expected term (in years)	5 years 6 months
Risk-free interest rate	0.64%
Maximum [Member]
Market value of common stock on issuance date	$ 0.84
Exercise price	$ 2
Expected volatility	138.00%
Expected term (in years)	6 years 6 months
Risk-free interest rate	1.73%

Stockholders' Deficit - Summary

Stockholders' Deficit - Summary of outstanding and exercisable Options (Details) - $ / shares	3 Months Ended	12 Months Ended
	Mar. 31, 2021	Dec. 31, 2020
Equity [Abstract]
Number of Options Outstanding, Beginning	7,125,000
Number of Options Granted	7,550,000
Number of Options Exercised	0
Number of Options Forfeited	0
Number of Options Expired	0
Number of Options Outstanding, Ending	14,675,000	7,125,000
Number of Options Exercisable	5,898,177
Weighted Average Exercise Price Outstanding, Beginning	$ 0.58
Weighted Average Exercise Price Granted	0.13
Weighted Average Exercise Price Exercised	0
Weighted Average Exercise Price Forfeited	0
Weighted Average Exercise Price Expired	0
Weighted Average Exercise Price Outstanding, Ending	0.35	$ 0.58
Weighted Average Exercise Price Exercisable	$ 0.45
Weighted Average Remaining Years Outstanding	9 years 6 months 7 days	9 years 3 months 19 days
Weighted Average Remaining Years granted	9 years 11 months 12 days
Weighted Average Remaining Years, Exercisable	9 years 3 months 11 days

Stockholders' Deficit - Summa_2

Stockholders' Deficit - Summary of outstanding and exercisable warrants (Details) - Warrants	3 Months Ended
	Mar. 31, 2021$ / sharesshares
Number of Warrants Outstanding, Beginning | shares	1,289,343
Number of Warrants Granted | shares	4,194,161
Number of Warrants Expired | shares	0
Number of Warrants Outstanding, Ending | shares	5,483,504
Weighted Average Exercise Price Outstanding, Beginning | $ / shares	$ 0.18
Weighted Average Exercise Price Granted | $ / shares	0.25
Weighted Average Exercise Price Expired | $ / shares	0
Weighted Average Exercise Price Outstanding, Ending | $ / shares	$ 0.20

Stockholders' Deficit (Details

Stockholders' Deficit (Details Narrative) - USD ($)	Jan. 15, 2021	Jan. 14, 2021	Jan. 13, 2021	Jan. 12, 2021	Jan. 04, 2021	Sep. 14, 2020	Jun. 08, 2020	May 04, 2020	Feb. 27, 2021	Feb. 10, 2021	Feb. 02, 2021	Feb. 01, 2021	Jan. 28, 2021	Dec. 28, 2020	Dec. 24, 2020	Sep. 23, 2020	Jun. 23, 2020	May 18, 2020	Feb. 29, 2020	Jan. 31, 2020	Dec. 31, 2019	Mar. 12, 2021	Mar. 12, 2021	Mar. 04, 2021	Mar. 02, 2021	Feb. 26, 2021	Feb. 22, 2021	Mar. 31, 2021	Mar. 25, 2021	Mar. 31, 2020	Dec. 31, 2020
Common Stock Description																												All common stock shares have equal voting rights, are non-assessable and have one vote per share. Voting rights are not cumulative, and therefore, the holders of more than 50% of the common stock could, if they choose to do so, elect all of the directors of the Company, subject to the rights of the preferred stockholders.
Common Stock, Par or Stated Value Per Share																												$ 0.0001
Common Stock, Shares Authorized																												200,000,000
Options granted, exercise price																												$ 0.13
Stock based compensation																												$ 382,473		$ 0
Unrecognized compensation expense																												$ 2,079,225
Common stock authorized under plan																												13,000,000			7,500,000
Number of stock sold		258,559							388,583	697,714			388,583													1,050,045	715,893		657,394
Proceeds from sale of stock													$ 51,410																$ 56,437
Interest rate																												0.50%
Debt conversion, converted instrument, shares issued			117,609	175,000	109,098					243,688	229,638	517,674													520,000
Debt conversion, converted instrument, amount			$ 10,000		$ 10,000					$ 20,000	$ 20,000	$ 45,000
Debt conversion, converted instrument, interest			$ 97		$ 272					$ 4,200		$ 162
Shares issued price per share	$ 0.22	$ 0.11		$ 0.10					$ 0.13	$ 0.09			$ 0.13									$ 0.13	$ 0.13	$ 0.22	$ 0.10	$ 0.09	$ 0.16		$ 0.14
Proceeds from related party debt		$ 28,571							$ 51,410	$ 121,577																$ 90,146	$ 115,617	$ 0	$ 56,437	$ 150,000
Shares issued for services, shares	29,167																							320,833
Shares issued for services, value																												$ 105,295
Warrant Exercisable																												5,483,504
Intrinsic value of warrants																												$ 33,258
Weighted average remaining contractual life of warrants outstanding																												4 years 6 months 3 days
Stock issued for deferred salary, shares																						692,308
Stock issued for deferred salary, value																						$ 90,000
Stock Option [Member]
Options granted						250,000		6,050,000						200,000	250,000	200,000		75,000				7,350,000	200,000
Options granted, exercise price						$ 0.84		$ 0.57						$ 0.18	$ 0.20	$ 0.80		$ 0.51				$ 0.13	$ 0.13
Vesting period						10 years		10 years						10 years	10 years	10 years		10 years				10 years	2 years
Value of option						$ 180,950		$ 3,152,050						$ 26,720	$ 180,950	$ 109,060		$ 34,260				$ 732,795	$ 19,940
Series B Preferred Stock [Member]
Preferred stock description																												Effective May 3, 2018, the Company’s Board of Directors authorized and designated 75 shares of the Company’s Preferred Stock as Series A Preferred Stock. Each share of the Series A Preferred Stock is entitled to a liquidation preference of $1,000 per share and is convertible into 1,000 shares of the Company’s common stock. The holders of a majority of the Series A Preferred Stock are entitled to elect up to four (4) directors to the Company’s board of directors and have preferential rights in regard to the election of Series A directors. In all other voting matters, the holders of Series A Preferred Stock are entitled to cast 1,000 votes per share.
Securities Purchase Agreement [Member]
Share Price																	$ 1.30											$ 0.09
Number of stock sold							36,666										115,385		50,000	100,000	100,000							1,696,838
Proceeds from sale of stock																			$ 50,000	$ 100,000	$ 100,000
Interest rate							12.00%										12.00%		8.00%	8.00%	8.00%
Warrant term							3 years												3 years	3 years
Letter Agreement
Number of stock sold										3,500,000
Shares issued price per share										$ 0.0001
Proceeds from related party debt										$ 1,207,500

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - Chief Executive Officer - USD ($)	2 Months Ended	3 Months Ended
	Mar. 12, 2021	Mar. 31, 2021
Monthly rent		$ 2,800
Accrued compensation		100,000
Related party cost		28,415
Repayment of accrued expenses		$ 40,000
Stock issued for compensation, shares	692,308	692,308
Stock issued for compensation, value		$ 90,000

Subsequent Events (Details Narr

Subsequent Events (Details Narrative)	1 Months Ended
	May 31, 2021USD ($)
Subsequent Event [Member]
Repayment of accrued expenses	$ 10,000